[go: up one dir, main page]

WO2008113364A3 - Prévention de la néphrotoxicité iii - Google Patents

Prévention de la néphrotoxicité iii Download PDF

Info

Publication number
WO2008113364A3
WO2008113364A3 PCT/DK2008/050070 DK2008050070W WO2008113364A3 WO 2008113364 A3 WO2008113364 A3 WO 2008113364A3 DK 2008050070 W DK2008050070 W DK 2008050070W WO 2008113364 A3 WO2008113364 A3 WO 2008113364A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
cell
cancer
treatment
amino derivatives
Prior art date
Application number
PCT/DK2008/050070
Other languages
English (en)
Other versions
WO2008113364A2 (fr
Inventor
Soeren Valdgaard Boye
Jacob Thinggaard
Original Assignee
Recepticon Aps
Soeren Valdgaard Boye
Jacob Thinggaard
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recepticon Aps, Soeren Valdgaard Boye, Jacob Thinggaard filed Critical Recepticon Aps
Priority to EP08715624A priority Critical patent/EP2139461A2/fr
Publication of WO2008113364A2 publication Critical patent/WO2008113364A2/fr
Publication of WO2008113364A3 publication Critical patent/WO2008113364A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention porte sur l'utilisation de composés pour la fabrication d'un médicament pour la prophylaxie et/ou le traitement d'une toxicité cellulaire induite, telle que la néphrotoxicité et l'ototoxicité, en particulier lorsque la toxicité cellulaire est induite par un traitement médical. Dans un mode de réalisation, les composés ont au moins deux atomes d'azote, et dans un mode préféré, au moins deux groupes amino. Les composés selon l'invention sont capables de bloquer la liaison de composés toxiques pour les cellules au récepteur de la mégaline, et d'inhiber ainsi l'absorption dans les cellules des composés toxiques pour celles-ci. L'invention porte en outre sur de nouveaux composés destinés à être utilisés dans ledit traitement, ainsi que sur un procédé pour réduire la toxicité cellulaire de composés toxiques pour les cellules.
PCT/DK2008/050070 2007-03-20 2008-03-19 Prévention de la néphrotoxicité iii WO2008113364A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP08715624A EP2139461A2 (fr) 2007-03-20 2008-03-19 Prévention de la néphrotoxicité iii

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200700424 2007-03-20
DKPA200700424 2007-03-20
DKPA200700958 2007-06-29
DKPA200700958 2007-06-29

Publications (2)

Publication Number Publication Date
WO2008113364A2 WO2008113364A2 (fr) 2008-09-25
WO2008113364A3 true WO2008113364A3 (fr) 2009-04-16

Family

ID=39529323

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2008/050070 WO2008113364A2 (fr) 2007-03-20 2008-03-19 Prévention de la néphrotoxicité iii

Country Status (2)

Country Link
EP (1) EP2139461A2 (fr)
WO (1) WO2008113364A2 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006259415B2 (en) 2005-06-15 2012-08-30 Massachusetts Institute Of Technology Amine-containing lipids and uses thereof
US8835506B2 (en) 2008-06-05 2014-09-16 Stc.Unm Methods and related compositions for the treatment of cancer
CN104910025B (zh) * 2008-11-07 2019-07-16 麻省理工学院 氨基醇类脂质和其用途
KR20210031549A (ko) * 2009-05-05 2021-03-19 알닐람 파마슈티칼스 인코포레이티드 지질 조성물
HUE038039T2 (hu) 2009-12-01 2018-09-28 Translate Bio Inc mRNS bejuttatása fehérjék és enzimek kiegészítésére humán genetikai betegségekben
EP2603215A4 (fr) 2010-08-11 2015-08-05 Philadelphia Health & Educatio Nouveaux agonistes du recepteur dopaminergique d3 pour traiter la dyskinesie dans la maladie de parkinson
EP2609135A4 (fr) 2010-08-26 2015-05-20 Massachusetts Inst Technology Poly(bêta-amino-alcools), leur préparation et utilisations de ceux-ci
EP2691443B1 (fr) 2011-03-28 2021-02-17 Massachusetts Institute of Technology Lipomères conjugués et utilisations associées
PL2717893T3 (pl) 2011-06-08 2019-12-31 Translate Bio, Inc. Kompozycje nanocząstek lipidowych i sposoby do dostarczania mRNA
WO2013063468A1 (fr) 2011-10-27 2013-05-02 Massachusetts Institute Of Technology Dérivés d'aminoacides fonctionnalisés sur le n-terminal, capables de former des microsphères d'encapsulation de médicament
CA2868463C (fr) * 2012-03-28 2021-01-19 University Of Central Florida Research Foundation, Inc. Agents therapeutiques selectifs en termes de transport des polyamines a stabilite plus elevee
JP2015521194A (ja) * 2012-05-30 2015-07-27 センソリオン 前庭毒性を処置するための方法
WO2013185067A1 (fr) 2012-06-08 2013-12-12 Shire Human Genetic Therapies, Inc. Polynucléotides résistant à la nucléase et leurs utilisations
CA2884870C (fr) 2012-08-13 2022-03-29 Massachusetts Institute Of Technology Lipidoides contenant des amines et leurs utilisations
IL290953B2 (en) 2013-03-14 2024-01-01 Ethris Gmbh CFTR mRNA Assemblies and Related Methods and Uses
AU2014236396A1 (en) 2013-03-14 2015-08-13 Shire Human Genetic Therapies, Inc. Methods for purification of messenger RNA
US9315472B2 (en) 2013-05-01 2016-04-19 Massachusetts Institute Of Technology 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
KR102096796B1 (ko) 2013-10-22 2020-05-27 샤이어 휴먼 지네틱 테라피즈 인크. 메신저 rna의 전달을 위한 지질 제형
CN106413811A (zh) 2013-10-22 2017-02-15 夏尔人类遗传性治疗公司 精氨基琥珀酸合成酶缺乏症的mrna疗法
EA201992208A1 (ru) 2013-10-22 2020-07-31 Транслейт Био, Инк. ЛЕЧЕНИЕ ФЕНИЛКЕТОНУРИИ С ПРИМЕНЕНИЕМ мРНК
KR102266696B1 (ko) 2013-10-28 2021-06-21 드렉셀유니버시티 주의력 및 인지 장애, 및 신경 퇴행성 장애와 관련된 치매 치료용 신규 치료제
SG11201608725YA (en) 2014-04-25 2016-11-29 Shire Human Genetic Therapies Methods for purification of messenger rna
CA3211902A1 (fr) 2014-05-30 2015-12-03 Translate Bio, Inc. Lipides biodegradables pour l'administration d'acides nucleiques
PE20171238A1 (es) 2014-06-24 2017-08-24 Shire Human Genetic Therapies Composiciones enriquecidas estereoquimicamente para administracion de acidos nucleicos
US9840479B2 (en) 2014-07-02 2017-12-12 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
CN107848988B (zh) 2015-06-19 2021-10-22 麻省理工学院 烯基取代的2,5-哌嗪二酮和其在组合物中用于向个体或细胞递送药剂的用途
WO2016210289A1 (fr) 2015-06-24 2016-12-29 Duke University Modulateurs chimiques des voies de signalisation et utilisation thérapeutique
WO2018157154A2 (fr) 2017-02-27 2018-08-30 Translate Bio, Inc. Nouvel arnm cftr à codons optimisés
US11173190B2 (en) 2017-05-16 2021-11-16 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of codon-optimized mRNA encoding CFTR
EP3841208A1 (fr) 2018-08-24 2021-06-30 Translate Bio, Inc. Procédés de purification d'arn messager
WO2020106946A1 (fr) 2018-11-21 2020-05-28 Translate Bio, Inc. Traitement de la fibrose kystique par administration d'arnm nébulisé codant pour la cftr
CN116763804A (zh) * 2023-07-10 2023-09-19 徐州工程学院 胡椒基哌嗪联合奈替米星在制备抗荧光假单胞菌感染药物中的应用

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07118148A (ja) * 1993-10-26 1995-05-09 Tsumura & Co 肝癌予防剤
US5474779A (en) * 1992-03-11 1995-12-12 Bufius; Nataliya Compositions for aiding in the regeneration of tissue with a prolonged immunomodulating effect
WO1998010757A2 (fr) * 1996-09-11 1998-03-19 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Utilisation d'antagonistes fonctionnels du n-methyl-d-aspartate pour reduire ou prevenir l'ototoxicite induite par l'aminoglucoside
US5763569A (en) * 1991-08-23 1998-06-09 The Brigham And Women's Hospital, Inc Calcium receptor-active molecules
WO1999022744A1 (fr) * 1997-11-05 1999-05-14 Geltex Pharmaceuticals, Inc. Reduction du niveau d'oxalates par des polyamines aliphatiques
WO1999051213A2 (fr) * 1998-04-03 1999-10-14 Theodore Toney Ilenchuk Utilisation de polyamines dans le traitement de symptomes dermatologiques
WO2003092668A1 (fr) * 2002-05-02 2003-11-13 Johannes Wohlrab Utilisation d'agmatine pour une application topique
WO2004084799A2 (fr) * 2003-03-27 2004-10-07 Jerachmiel Appelbaum Compositions pharmaceutiques destinees a inhiber l'activite enzymatique dependante des ions metalliques et techniques d'utilisation de celles-ci
WO2004084876A2 (fr) * 2003-03-26 2004-10-07 Recepticon Aps Utilisation de composes pour prevenir la toxicite cellulaire induite par un medicament
US20050085555A1 (en) * 1997-08-21 2005-04-21 Murphy Michael A. Composition, synthesis and therapeutic applications of polyamines
WO2005060569A2 (fr) * 2003-12-11 2005-07-07 Ludwig Institute For Cancer Research Chelateurs a base de tame et utilisations de ceux-ci
WO2006037335A2 (fr) * 2004-10-06 2006-04-13 Recepticon Aps Utilisation de composes pour la prevention d'une toxicite cellulaire induite par un medicament
WO2006040579A1 (fr) * 2004-10-14 2006-04-20 The University Court Of The University Of Glasgow Polymeres bioactifs
WO2006119713A2 (fr) * 2005-05-12 2006-11-16 Centro De Ingenieria Genetica Y Biotecnologia Composes a action antineoplasique et compositions pharmaceutiques les contenant
WO2008107471A2 (fr) * 2007-03-07 2008-09-12 Dextech Medical Ab Conjugués d'hydroxypolymère modifié à activité destructrice de cellules tumorales

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763569A (en) * 1991-08-23 1998-06-09 The Brigham And Women's Hospital, Inc Calcium receptor-active molecules
US5474779A (en) * 1992-03-11 1995-12-12 Bufius; Nataliya Compositions for aiding in the regeneration of tissue with a prolonged immunomodulating effect
JPH07118148A (ja) * 1993-10-26 1995-05-09 Tsumura & Co 肝癌予防剤
WO1998010757A2 (fr) * 1996-09-11 1998-03-19 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Utilisation d'antagonistes fonctionnels du n-methyl-d-aspartate pour reduire ou prevenir l'ototoxicite induite par l'aminoglucoside
US20050085555A1 (en) * 1997-08-21 2005-04-21 Murphy Michael A. Composition, synthesis and therapeutic applications of polyamines
WO1999022744A1 (fr) * 1997-11-05 1999-05-14 Geltex Pharmaceuticals, Inc. Reduction du niveau d'oxalates par des polyamines aliphatiques
WO1999051213A2 (fr) * 1998-04-03 1999-10-14 Theodore Toney Ilenchuk Utilisation de polyamines dans le traitement de symptomes dermatologiques
WO2003092668A1 (fr) * 2002-05-02 2003-11-13 Johannes Wohlrab Utilisation d'agmatine pour une application topique
WO2004084876A2 (fr) * 2003-03-26 2004-10-07 Recepticon Aps Utilisation de composes pour prevenir la toxicite cellulaire induite par un medicament
WO2004084799A2 (fr) * 2003-03-27 2004-10-07 Jerachmiel Appelbaum Compositions pharmaceutiques destinees a inhiber l'activite enzymatique dependante des ions metalliques et techniques d'utilisation de celles-ci
WO2005060569A2 (fr) * 2003-12-11 2005-07-07 Ludwig Institute For Cancer Research Chelateurs a base de tame et utilisations de ceux-ci
WO2006037335A2 (fr) * 2004-10-06 2006-04-13 Recepticon Aps Utilisation de composes pour la prevention d'une toxicite cellulaire induite par un medicament
WO2006040579A1 (fr) * 2004-10-14 2006-04-20 The University Court Of The University Of Glasgow Polymeres bioactifs
WO2006119713A2 (fr) * 2005-05-12 2006-11-16 Centro De Ingenieria Genetica Y Biotecnologia Composes a action antineoplasique et compositions pharmaceutiques les contenant
WO2008107471A2 (fr) * 2007-03-07 2008-09-12 Dextech Medical Ab Conjugués d'hydroxypolymère modifié à activité destructrice de cellules tumorales

Non-Patent Citations (20)

* Cited by examiner, † Cited by third party
Title
BASU, HIRAK S. ET AL: "Correlation between the effects of polyamine analogs on DNA conformation and cell growth", CANCER RESEARCH , 49(20), 5591-7 CODEN: CNREA8; ISSN: 0008-5472, 1989, XP007906534 *
BRANA, M. F. ET AL: "Chromophore-Modified Bis-Naphthalimides: Synthesis and Antitumor Activity of Bis-Dibenz[de,h]isoquinoline-1,3-diones", JOURNAL OF MEDICINAL CHEMISTRY , 40(4), 449-454 CODEN: JMCMAR; ISSN: 0022-2623, 1997, XP007906538 *
CAMPHAUSEN K ET AL: "Evaluation of chelating agents as anti-angiogenic therapy through copper chelation", BIOORGANIC & MEDICINAL CHEMISTRY, ELSEVIER SCIENCE LTD, GB, vol. 12, no. 19, 1 October 2004 (2004-10-01), pages 5133 - 5140, XP004558891, ISSN: 0968-0896 *
COVASSIN, LAURENCE ET AL: "Synthesis of spermidine and norspermidine dimers as high affinity polyamine transport inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS , 9(12), 1709-1714 CODEN: BMCLE8; ISSN: 0960-894X, 1999, XP002506782 *
COVASSIN, LAURENCE ET AL: "Xylylated dimers of putrescine and polyamines: influence of the polyamine backbone on spermidine transport inhibition", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS , 13(19), 3267-3271 CODEN: BMCLE8; ISSN: 0960-894X, 2003, XP007906533 *
DIMMOCK J ET AL: "Mannich bases of phenolic azobenzenes possessing cytotoxic activity", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, vol. 32, no. 7-8, 1 July 1997 (1997-07-01), pages 583 - 594, XP004372794, ISSN: 0223-5234 *
EDWARDS M L ET AL: "POLYAMINE ANALOGUES WITH ANTITUMOR ACTIVITY. POLYAMINE ANALOGUES WITH ANTITUMOR ACTIVITY", JOURNAL OF MEDICINAL CHEMISTRY, US AMERICAN CHEMICAL SOCIETY. WASHINGTON, vol. 33, no. 5, 1 May 1990 (1990-05-01), pages 1369 - 1375, XP000604648, ISSN: 0022-2623 *
LEVINE, SEYMOUR ET AL: "Hypothalamic and medullary lesions caused by an aliphatic triamine unrelated to goldthioglucose", JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY , 41(1), 54-66 CODEN: JNENAD; ISSN: 0022-3069, 1982, XP009109539 *
MUIR C P ET AL: "Nitric oxide attenuates resistance to doxorubicin in three-dimensional aggregates of human breast carcinoma cells", BREAST CANCER RESEARCH AND TREATMENT, KLUWER ACADEMIC PUBLISHERS, BO, vol. 96, no. 2, 1 March 2006 (2006-03-01), pages 169 - 176, XP019274993, ISSN: 1573-7217 *
NG, CHIU YUEN ET AL: "1,4-Bis[2,5,5-tris(carboxymethyl)-2,5-diazapentyl]benzene (PXED3A): synthesis, binuclear chelating tendencies, and iron(III) .mu.-oxo-bridge formation", INORGANIC CHEMISTRY , 22(5), 721-8 CODEN: INOCAJ; ISSN: 0020-1669, 1983, XP007906530 *
OGUCHI, HISAO ET AL: "Effect of lactose derivatives on metastatic potential of B16 melanoma cells", CANCER COMMUNICATIONS , 2(9), 311-16 CODEN: CNCMET; ISSN: 0955-3541, 1990, XP009109561 *
PALMER, BRIAN D. ET AL: "Synthesis, DNA binding interactions and biological activity of bis-platinum (II) complexes of N,N,N',N'-tetrakis(2-aminoethyl)diamines", ANTI-CANCER DRUG DESIGN , 7(5), 385-401 CODEN: ACDDEA; ISSN: 0266-9536, 1992, XP002939720 *
RUSTENBECK I ET AL: "Polyamine modulation of mitochondrial calcium transport. II. Inhibition of mitochondrial permeability transition by aliphatic polyamines but not by aminoglucosides.", BIOCHEMICAL PHARMACOLOGY 15 OCT 1998, vol. 56, no. 8, 15 October 1998 (1998-10-15), pages 987 - 995, XP007906535, ISSN: 0006-2952 *
RUSTENBECK, INGO ET AL: "Polyamine modulation of mitochondrial calcium transport, I. Stimulatory and inhibitory effects of aliphatic polyamines, aminoglycosides and other polyamine analogs on mitochondrial calcium uptake", BIOCHEMICAL PHARMACOLOGY , 56(8), 977-985 CODEN: BCPCA6; ISSN: 0006-2952, 1998, XP007906539 *
SHA, S.-H. ET AL: "Antioxidants attenuate gentamicin-induced free radical formation in vitro and ototoxicity in vivo: D-methionine is a potential protectant", HEARING RESEARCH , 142(1-2), 34-40 CODEN: HERED3; ISSN: 0378-5955, 2000, XP007906532 *
SHAH, NEHA ET AL: "Activation of Nuclear Factor .kappa.B by Polyamines in Breast Cancer Cells", BIOCHEMISTRY , 38(45), 14763-14774 CODEN: BICHAW; ISSN: 0006-2960, 1999, XP007906536 *
SIBERT, JOHN W. ET AL: "Lipophilic derivatives of cyclam as new inhibitors of tumor cell growth", CHEMICAL COMMUNICATIONS (CAMBRIDGE, UNITED KINGDOM) , (2), 154-155 CODEN: CHCOFS; ISSN: 1359-7345, 2002, XP007906537 *
TAKAO K ET AL: "Studies on inhibition of enzymatic arginyltransfer reaction", CHEMICAL AND PHARMACEUTICAL BULLETIN, PHARMACEUTICAL SOCIETY OF JAPAN, TOKYO, vol. 46, no. 7, 1 January 1998 (1998-01-01), pages 1169 - 1172, XP009109711, ISSN: 0009-2363 *
WILLIAMS P D ET AL: "Inhibition of renal membrane binding and nephrotoxicity of aminoglycosides", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, AMERICAN SOCIETY FOR PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, US, vol. 237, no. 3, 1 January 1986 (1986-01-01), pages 919 - 925, XP009109529, ISSN: 0022-3565 *
ZANG, ERLE ET AL: "Synthesis of hexamine ligands by using trityl as an N-blocking group", SYNTHETIC COMMUNICATIONS , 27(18), 3145-3150 CODEN: SYNCAV; ISSN: 0039-7911, 1997, XP009109581 *

Also Published As

Publication number Publication date
WO2008113364A2 (fr) 2008-09-25
EP2139461A2 (fr) 2010-01-06

Similar Documents

Publication Publication Date Title
WO2008113364A3 (fr) Prévention de la néphrotoxicité iii
WO2004084876A3 (fr) Utilisation de composes pour prevenir la toxicite cellulaire induite par un medicament
PH12012502057A1 (en) Compounds for inhibiting mitotic progression
WO2007133637A3 (fr) Dérivés d'amides en tant que ligands de canal ionique et compositions pharmaceutiques et méthodes d'utilisation desdits dérivés
NZ577916A (en) Cyclopamine analogs
WO2008021038A3 (fr) Pyridobenzazépines et méthodes d'inhibition de la progression mitotique
NZ609344A (en) Method for treatment of diarrhea-predominant irritable bowel syndrome
WO2008024978A3 (fr) Dérivés de benzène, de pyridine et de pyridazine
WO2007109192A3 (fr) Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 et leurs utilisations
WO2008012532A3 (fr) Composés chimiques 428
WO2007109172A3 (fr) Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 et leurs utilisations
WO2006102610A3 (fr) Composes bicycloheteroaryle utilises en tant que modulateurs de p2x7 et leurs utilisations
WO2007109154A3 (fr) Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 modulators et leurs utilisations
MX2009012155A (es) Combinación farmacéutica sinérgica para el tratamiento de cáncer.
UA105390C2 (ru) МОТИВЫ ХИМИЧЕСКИХ МОДИФИКАЦИЙ ДЛЯ ИНГИБИТОРОВ И МИМЕТИКОВ мкРНК
WO2007109160A3 (fr) Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 et leurs utilisations
WO2007024843A3 (fr) Inhibiteurs de pyrimidinyl-pyrazole d'aurora kinases
WO2008013987A3 (fr) Pipérazinylméthylquinazolinones et azépanylméthylquinazolinones à substitution n-alkyle
WO2007109182A3 (fr) Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 et leurs utilisations
WO2011058027A3 (fr) Composés de purine n-9-substitués, compositions et procédés d'utilisation
WO2007109201A3 (fr) Composés de bicyclohétéroaryle en tant que modulateur de p2x7 et leurs utilisations
AU2007249926A8 (en) Monocyclic heteroaryl compounds
MX2009012523A (es) Composiciones utiles para reducir la nefrotoxicidad y metodos para utilizarlas.
EP2215054B8 (fr) Dérivés amide à titre de ligands des canaux ioniques et compositions pharmaceutiques et procédés d'utilisation correspondants
WO2008002460A3 (fr) Composés antinéoplasiques indépendants de la lumière disponibles sous une forme orale

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08715624

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008715624

Country of ref document: EP